KALARIS THERAPEUTICS, INC. Capital Expenditures
KALARIS THERAPEUTICS, INC. (KLRS) reported Capital Expenditures of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-03-17
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $17.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2021-12-31 was -$370.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2021-09-30 was $33.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2021-06-30 was $288.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $200.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $26.00K, a 88.94% decline from fiscal 2020.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $235.00K, a 30.68% decline from fiscal 2019.
- KALARIS THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $339.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $200.00K 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $183.00K 10-Q · filed 2025-11-12 | |||
| 2021-12-31 | -$370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$337.00K derived: sum of 2 quarters · filed 2023-02-15 | -$49.00K derived: sum of 3 quarters · filed 2023-02-15 | $26.00K 10-K · filed 2023-02-15 |
| 2021-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $321.00K derived: sum of 2 quarters · filed 2022-11-03 | $396.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $363.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $75.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $235.00K 10-K · filed 2022-02-10 | |||
| 2019-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $114.00K derived: sum of 2 quarters · filed 2021-02-12 | $339.00K 10-K · filed 2021-02-12 | |
| 2019-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $218.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $225.00K 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |